This clinical trial is focused on studying a condition known as Higher-Risk Myelodysplastic Syndrome (MDS). MDS is a group of disorders caused by poorly formed or dysfunctional blood cells. The study is evaluating the effectiveness and safety of a treatment that combines two medications: Venetoclax and Azacitidine. Venetoclax is a medication that works by blocking a protein that helps cancer cells survive, while Azacitidine is used to help the bone marrow produce normal blood cells and reduce the need for blood transfusions.

The purpose of this study is to determine if adding Venetoclax to the standard treatment with Azacitidine can improve the overall survival of patients who have been newly diagnosed with higher-risk MDS. Participants in the study will be randomly assigned to receive either the combination of Venetoclax and Azacitidine or a placebo with Azacitidine. A placebo is a substance with no active medication, used to compare the effects of the actual treatment. The study will be conducted over a period of time, and participants will receive the treatment in cycles, with regular monitoring by healthcare professionals to assess their response to the treatment.

Throughout the study, various aspects of the participants’ health will be monitored, including their overall response to the treatment, any improvements in blood cell counts, and their need for blood transfusions. The study will also look at how the treatment affects participants’ physical functioning and fatigue levels. The main goal is to see if the combination of Venetoclax and Azacitidine can help patients live longer and improve their quality of life compared to the standard treatment alone.